Table 2.
Type of CARV and mortality by CARV type and timing of respiratory virus infection and CARV upper or lower respiratory tract disease
| EvRh | RSV | Influ | HPiV | hMPV | AdV | HCoV | HBoV | |
|---|---|---|---|---|---|---|---|---|
| Number of episodes, n (%)a | 145 (39) | 100 (27) | 58 (15) | 65 (17) | 38 (10) | 8 (2) | 24 (6) | 10 (3) |
| 90-day overall mortality, n (%)a | 10 (7) | 12 (12) | 3 (5) | 5 (8) | 3 (8) | 1 (13) | 2 (8) | 0 |
| CARV URTD, n (%)a | 102 (70) | 54 (54) | 38 (65) | 37 (72) | 21 (55) | 2 (25) | 18 (75) | 9 (90) |
| 90-day overall mortality, n (%)a | 3 (3) | 2 (4) | 1 (3) | 2 (5) | 1 (5) | 0 | 1 (6) | 0 |
| CARV URTD from day −7 until day +180, na | 64 (63) | 30 (56) | 18 (47) | 22 (59) | 14 (67) | 1 (50) | 10 (56) | 5 (56) |
| 90-day overall mortality, na | 3 (5) | 2 (7) | 1 (5) | 1 (4) | 1 (7) | 0 | 1 (10) | 0 |
| CARV URTD from day +181 until 1 year, na | 38 (37) | 24 (44) | 20 (53) | 15 (41) | 7 (33) | 1 (50) | 8 (44) | 4 (44) |
| 90-day overall mortality, n (%)a | 0 | 0 | 0 | 1 (7) | 0 | 0 | 0 | 0 |
| CARV LRTD, n (%)a | 43 (30) | 46 (46) | 20 (35) | 18 (28) | 17 (45) | 6 (75) | 6 (25) | 1 (10) |
| 90-day overall mortality, n (%)a | 7 (16) | 10 (22) | 2 (10) | 3 (17) | 2 (12) | 1 (17) | 1 (17) | 0 |
| CARV LRTD from day −7 until day +180, na | 29 (67) | 29 (63) | 14 (70) | 13 (72) | 13 (76) | 4 (67) | 3 (50) | 1 (100) |
| 90-day overall mortality, n (%)a | 5 (17) | 9 (31) | 2 (14) | 2 (15) | 2 (15) | 1 (25) | 1 (33) | 0 |
| CARV LRTD from day +181 until 1 year, na | 14 (33) | 17 (37) | 6 (30) | 5 (28) | 4 (24) | 2 (33) | 3 (50) | 0 |
| 90-day overall mortality, n (%)a | 2 (14) | 1 (6) | 0 | 1 (20) | 0 | 0 | 0 | 0 |
CARV community-acquired respiratory virus, EvRh enterovirus/rhinovirus, ADV adenovirus, RSV respiratory syncytial virus, HPiV human parainfluenza virus, hMPV human metapneumovirus, HCoV human coronavirus, Influ human influenza virus, AdV adenovirus, IFD invasive pulmonary fungal disease, URTD upper respiratory tract disease, LRTD lower respiratory tract disease
aThe sum total of the episodes does not match the overall number of episodes (n = 376) since multiple CARVs were detected in the same respiratory sample in 72 (19%) CARV episodes. 90-day all-cause mortality after CARV coviral infection was 8% (6 out of 72). Forty-one covirus infectious episodes occurred within the first 6 months after stem cell infusion and mortality was 15% (6 out of 41). Two (5%) out of 44 with URTD and four (14%) out of 28 patients with LRTD CARV coviral infection died. Finally, 4 (24%) out of 17 patients with LRTD CARV coviral infection occurring within the first 6 months after stem cell infusion died